MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2023.11.068

Медицинская библиотека · Journal of the American Academy of Dermatology · 2024

Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.

Fiorillo Loretta, Becker Emily, de Lucas Raul, Belloni-Fortina Anna, Armesto Susana, Elewski Boni, Maes Peter, Oberoi Rajneet K, Paris Maria, Zhang Wendy, Zhang Zuoshun, Arkin Lisa

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Approved systemic treatment options are limited for pediatric patients with moderate to severe plaque psoriasis.

OBJECTIVE

To assess the efficacy and safety of apremilast over 16 weeks in pediatric patients with plaque psoriasis.

METHODS

SPROUT (NCT03701763) was a phase 3, multicenter, randomized, double-blind, placebo-controlled study of apremilast in patients aged 6-17 years with moderate-to-severe psoriasis (Psoriasis Area and Severity Index [PASI] ≥12, body surface area ≥10%, static Physician Global Assessment [sPGA] ≥3) inadequately controlled by/inappropriate for topical therapy. Patients were stratified by age group and randomized (2:1) to apremilast (20 or 30 mg BID based on weight) or placebo for 16 weeks, followed by apremilast extension to 52 weeks.

RESULTS

Of 245 patients randomized (apremilast: 163; placebo: 82), 221 (90%) completed the double-blind phase (apremilast: 149; placebo: 72). Significantly more patients achieved sPGA response and ≥75% reduction in PASI with apremilast than placebo, regardless of baseline age, weight, or disease severity. No new safety signals were observed.

LIMITATIONS: Sample size of subgroup analyses.

CONCLUSIONS

Improvements in global disease activity and skin involvement were significantly greater in pediatric patients treated with apremilast versus placebo. Adverse events were consistent with the known apremilast safety profile.

Для цитирования: Fiorillo Loretta, Becker Emily, de Lucas Raul, Belloni-Fortina Anna, Armesto Susana, Elewski Boni, Maes Peter, Oberoi Rajneet K, Paris Maria, Zhang Wendy, Zhang Zuoshun, Arkin Lisa. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.. Journal of the American Academy of Dermatology. 2024. DOI: 10.1016/j.jaad.2023.11.068.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.